. . . "(-)-2-(2,2-Dicyclohexylethyl)piperidine"@en . "Perhexilinum"@en . "Perhexiline and its metabolites are highly protein bound (>90%)."@en . . . . . . . . . . . . "Perhexilline"@en . . . . . . "Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency."@en . . . "2-(2,2-Dicyclohexylethyl)piperidine"@en . . "2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]"@en . "Perhexilina"@en . . . . . . "Oral LD₅₀ rat: 2150 mg/kg; Oral LD₅₀ Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare)."@en . . "Well absorbed (>80%) from the gastrointestinal tract following oral administration."@en . . "For the management of severe angina pectoris."@en . "Stephen W. Horgan, Frank P. Palopoli, Edward J. Schwoegler, \"Process for preparing 2-(2,2-dicyclohexylethyl)piperidine.\" U.S. Patent US4069222, issued August, 1950."@en . "Perhexilene"@en . . . "(+)-2-(2,2-Dicyclohexylethyl)piperidine"@en . "Perhexiline"@en . "Humans and other mammals"@en . . "approved"@en . . . . . "Perhexiline"@en . " "@en . . . "6621-47-2"@en . "Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days."@en . .